![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Department of Life Science (J.-S.K., J.-Y.P., H.-W.K., E.-J.L., J.-H.L.) and Interdisciplinary Program of Integrated Biotechnology (J.-H.L.), Sogang University, Seoul, Korea; and Department of Physiology (H.B.), Chung-Ang University, Seoul, Korea
TWIK-related K+ channel (TREK)-2 is thought to contribute to setting the resting membrane potential and to tuning action potential properties. In the present study, the effects of divalent metal ions (Ba2+, Co2+, Ni2+, Pb2+, and Zn2+) were examined on TREK-2 expressed in Xenopus oocytes using the two-electrode voltage clamping technique. Pb2+ inhibited TREK channel activity (IC50 = 15.6 µM), whereas Zn2+ enhanced it in a dose-dependent manner (EC50 = 87.1 µM). Ba2+ slightly inhibited TREK currents but only at high concentrations. Co2+ and Ni2+ had no significant effect. The structural element(s) contributing to the zinc enhancement effect were studied using a series of chimeras consisting of Zn2+-activated TREK-2 and Zn2+-inhibited TWIK-related acid-sensing K+ channel-3. The structural elements were localized to the first pore and the preceding extracellular loop of TREK-2, in which multiple residues, including His121, His156, Asp158, and Asn177, are likely to be involved in the zinc activation effect. Stimulation by Zn2+ may be used as a criterion of TREK-2, distinguishing it from other two-pore K+ channels.
Address correspondence to: Dr. Jung-Ha Lee, Department of Life Science, Sogang University, Mapo-Gu, Sinsu-Dong 1, Seoul 121-742, Korea. E-mail: jhleem{at}ccs.sogang.ac.kr
This article has been cited by other articles:
![]() |
A. Traboulsie, J. Chemin, M. Chevalier, J.-F. Quignard, J. Nargeot, and P. Lory Subunit-specific modulation of T-type calcium channels by zinc J. Physiol., January 1, 2007; 578(1): 159 - 171. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Czirjak and P. Enyedi Zinc and Mercuric Ions Distinguish TRESK from the Other Two-Pore-Domain K+ Channels Mol. Pharmacol., March 1, 2006; 69(3): 1024 - 1032. [Abstract] [Full Text] [PDF] |
||||